TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
View original at seekingalpha.comTransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion Earnings Call Insights: TransMedics Group, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
NOP Connect 2.0 showing efficiency in management and billing, though these are early days
80% confidenceLiver market share gains represent pure TransMedics execution excellence
80% confidenceWhat's coming is the unequivocal drop-the-mic statistical superiority in the most important outcomes after liver transplantation, referring to upcoming registry publication
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidenceNOP Connect 2.0 is showing efficiency in management and billing, though these are early days
80% confidenceTransMedics is just getting started and has sights focused on new peaks
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceOperating profit of approximately $21.3 million in Q4 represented approximately 13.2% of total revenue
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million
80% confidenceOCS was responsible for 5,139 U.S. transplants in 2025, up from 3,735 in 2024
80% confidenceMost lung transplant centers were waiting for FDA approval before launching into DENOVO program
80% confidenceTransMedics continues to expect operating margins to approach 30% by 2028
80% confidenceOUS transplant revenue grew approximately 33% sequentially to $5 million
80% confidenceAlmost 50% of the incremental investment in 2026 is driven by really 3 elements and those, by nature, are transitory
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million in Q4 2025
80% confidenceOCS Heart comprised 18% of heart transplants in 2025, up from 17% in 2024
80% confidenceTotal revenue for Q4 was approximately $161 million with U.S. transplant revenue of approximately $155 million, up 33% year-over-year and 11% sequentially
80% confidenceQ4 2025 total revenue was approximately $161 million, with U.S. transplant revenue of approximately $155 million, up 33% year-over-year and 11% sequentially
80% confidenceTransMedics is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceMost of the lung centers were waiting to see the FDA approval to start launching into DENOVO
80% confidenceThe makers of that styrofoam box (competitor) is refusing to randomize their technology to TransMedics in ENHANCE Part B trial
80% confidence2026 operating margins expected to be up to approximately 250 basis points below 2025 full year levels, primarily reflecting timing and scale of investments
80% confidenceAlmost 50% of incremental investment in 2026 is driven by three elements that are transitory by nature
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceCompany is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceOUS transplant revenue grew approximately 33% sequentially to $5 million
80% confidenceTransMedics was prepared and expected ENHANCE Part B trial challenges, and will execute Part B hoping for significant success
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidenceTransMedics achieved its best operational performance to date in Q4 2025
80% confidenceThe makers of the styrofoam box technology are refusing to randomize their technology against TransMedics in ENHANCE Part B trial
80% confidence